معرفی
Peter G. Manza is an Assistant Professor in the Department of Psychiatry at the University of Maryland School of Medicine, with an additional appointment at the Kahlert Institute for Addiction Medicine. His work bridges clinical psychiatry and neuroscience to address substance use disorders through advanced neuroimaging and therapeutic interventions.
His educational background includes:
- 2011: BA in Biology and Psychology from the University of Rochester
- 2013: MA in Psychology from Stony Brook University
- 2016: PhD in Integrative Neuroscience from Stony Brook University (Thesis Advisor: Hoi-Chung Leung)
Dr. Manza's research centers on addiction mechanisms, with emphasis on dopamine dynamics, brain stimulation therapies, and novel treatments like ketamine and ketogenic diets. He employs fMRI and PET to map neural circuits underlying drug reward, craving, and age-related vulnerabilities in substance use disorders. His work has significant implications for developing targeted pharmacotherapies.
Analysis of his 2020-2024 publications reveals a cohesive trajectory exploring dopamine's dual signaling modes in addiction, structural brain changes in cannabis dependence, and metabolic interventions for alcohol use disorder. Key trends include differentiation of fast/slow dopamine pathways in reward processing, striatal receptor variations across age groups, and translational applications of dietary therapies.
His scientific contributions have been recognized through prestigious awards:
- Early Career Investigator Award from the Society of Biological Psychiatry
- NARSAD BRRF Young Investigator Award
- Conan Kornetsky Travel Award from the Winter Conference on Brain Research
- Athina Markou Travel Award from the American College on Neuropsychopharmacology
As an ACNP Associate Member, Dr. Manza contributes to national addiction research initiatives. His current work at the Kahlert Institute focuses on clinical trials for neurobiological craving reduction, with no public information regarding student advising or specific grant funding. The institute provides infrastructure for his translational studies on dopamine-modulating therapies.
